Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK

Li,Weilong; Wang,Dong; Li,Meijing; Li,Baoyuan

doi:10.3892/etm.2021.10509

Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK

Authors:
- Weilong Li
- Dong Wang
- Meijing Li
- Baoyuan Li
View Affiliations

Affiliations: Department of Nuclear Medicine, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Thyroid, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Hepatobiliary, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: July 28, 2021 https://doi.org/10.3892/etm.2021.10509
Article Number: 1075
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emodin has been demonstrated to serve antitumor roles in a variety of tumor types, but the effect of emodin on papillary thyroid carcinoma and its molecular mechanisms remain unclear. In the current study, the role of emodin on papillary thyroid carcinoma was analyzed in vitro and in vivo. TPC‑1 cells were treated with emodin (0, 10, 25 or 50 µM), and cell viability and apoptosis were detected using Cell Counting Kit‑8 and flow cytometry, respectively. The expression levels of AMPK‑associated proteins were examined using western blot analysis. To study the effect of emodin on the AMPK pathway, AMPK activator, AICAR and an AMPK inhibitor, Dorsomorphin, were used in TPC‑1 cells. In vivo, mice were used to confirm the mechanism of emodin on papillary thyroid carcinoma. The results of the current study indicated that emodin treatment induced cell apoptosis and cell cycle arrest in TPC‑1 cells. Furthermore, the inhibitory effect increased in a dose dependent manner. Following emodin treatment, the cell viability of TPC‑1 cells was significantly decreased, and apoptosis rate increased (P<0.05). Furthermore, the expression levels of AMPK were increased in the emodin group compared with the control group (P<0.05). Similar effects were observed following AMPK activator treatment in TPC‑1 cells. Following AMPK activator treatment, cell proliferation and the cell cycle were inhibited. Also, the AMPK inhibitor was demonstrated to mediate the therapeutic effect of emodin. In addition, the results of the present study demonstrated that emodin inhibited the MEK/ERK pathway. Additionally, the in vivo results of the current study were consistent with those in vitro. In conclusion, the current study demonstrated that the administration of Emodin inhibited the proliferation of papillary thyroid cancer cells via activating AMPK pathway activity.

View Figures

View References

1	Sak SD: Variants of papillary thyroid carcinoma: Multiple faces of a familiar tumor. Turk Patoloji Derg. 31 (Suppl 1):S34–S47. 2015.PubMed/NCBI View Article : Google Scholar
2	Lam AK and Saremi N: Cribriform-morular variant of papillary thyroid carcinoma: A distinctive type of thyroid cancer. Endocr Relat Cancer. 24:R109–R121. 2017.PubMed/NCBI View Article : Google Scholar
3	Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV and Asioli S: Hobnail variant of papillary thyroid carcinoma: A literature review. Endocr Pathol. 28:293–301. 2017.PubMed/NCBI View Article : Google Scholar
4	Stoffer SS: Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 7th edition. Lippincott Williams & Wilkins, Philadelphia, PA, 1996.
5	Su J, Yan Y, Qu J, Xue X, Liu Z and Cai H: Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway. Oncol Rep. 37:1565–1572. 2017.PubMed/NCBI View Article : Google Scholar
6	Li N, Wang C, Zhang P and You S: Emodin inhibits pancreatic cancer EMT and invasion by up-regulating microRNA-1271. Mol Med Rep. 18:3366–3374. 2018.PubMed/NCBI View Article : Google Scholar
7	Kim YS, Lee YM, Oh TI, Shin DH, Kim GH, Kan SY, Kang H, Kim JH, Kim BM, Yim WJ and Lim JH: Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. Int J Mol Sci. 19(3127)2018.PubMed/NCBI View Article : Google Scholar
8	Tang Q, Wu J, Zheng F, Hann SS and Chen Y: Emodin increases expression of insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer. Cell Physiol Biochem. 41:339–357. 2017.PubMed/NCBI View Article : Google Scholar
9	Tseng HS, Wang YF, Tzeng YM, Chen DR, Liao YF, Chiu HY and Hsieh WT: Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells. Am J Chin Med. 45:337–350. 2017.PubMed/NCBI View Article : Google Scholar
10	Tang Q, Zhao S, Wu J, Zheng F, Yang L, Hu J and Hann SS: Inhibition of integrin-linked kinase expression by emodin through crosstalk of AMPKα and ERK1/2 signaling and reciprocal interplay of Sp1 and c-Jun. Cell Signal. 27:1469–1477. 2015.PubMed/NCBI View Article : Google Scholar
11	Yu H, Xie Y, Zhou Z, Wu Z, Dai X and Xu B: Curcumin regulates the progression of colorectal cancer via LncRNA NBR2/AMPK pathway. Technol Cancer Res Treat. 18(1533033819870781)2019.PubMed/NCBI View Article : Google Scholar
12	Chen D, Wu YX, Qiu YB, Wan BB, Liu G, Chen JL, Lu MD and Pang QF: Hyperoside suppresses hypoxia-induced A549 survival and proliferation through ferrous accumulation via AMPK/HO-1 axis. Phytomedicine. 67(153138)2020.PubMed/NCBI View Article : Google Scholar
13	Samuels JS, Shashidharamurthy R and Rayalam S: Novel anti-obesity effects of beer hops compound xanthohumol: Role of AMPK signaling pathway. Nutr Metab (Lond). 15(42)2018.PubMed/NCBI View Article : Google Scholar
14	Wu CC, Chen MS, Cheng YJ, Ko YC, Lin SF, Chiu IM and Chen JY: Emodin inhibits EBV reactivation and represses NPC tumorigenesis. Cancers (Basel). 11(1795)2019.PubMed/NCBI View Article : Google Scholar
15	Tsai WL, Hsu CN and Tain YL: Whether AICAR in pregnancy or lactation prevents hypertension programmed by high saturated fat diet: A pilot study. Nutrients. 12(448)2020.PubMed/NCBI View Article : Google Scholar
16	Hasanvand A, Amini-Khoei H, Hadian MR, Abdollahi A, Tavangar SM, Dehpour AR, Semiei E and Mehr SE: Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy. Inflammopharmacology. 24:207–219. 2016.PubMed/NCBI View Article : Google Scholar
17	Guo JM, Xiao BX, Liu Q, Zhang S, Liu DH and Gong ZH: Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol Sin. 28:1991–1995. 2007.PubMed/NCBI View Article : Google Scholar
18	Hsu LC, Tu HF, Hsu FT, Yueh PF and Chiang IT: Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model. Biomed Pharmacother. 126(110054)2020.PubMed/NCBI View Article : Google Scholar
19	Yasemin S, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L and Sabatini DM: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 320:1496–1501. 2008.PubMed/NCBI View Article : Google Scholar
20	Hardie DG: AMPK-sensing energy while talking to other signaling pathways. Cell Metab. 20:939–952. 2014.PubMed/NCBI View Article : Google Scholar
21	Carling D: AMPK signalling in health and disease. Curr Opin Cell Biol. 45:31–37. 2017.PubMed/NCBI View Article : Google Scholar
22	Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.PubMed/NCBI View Article : Google Scholar
23	Lin W, Zhong M, Yin H, Chen Y, Cao Q, Wang C and Ling C: Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo. Oncol Rep. 36:961–967. 2016.PubMed/NCBI View Article : Google Scholar